GLAS // Glass House Brands Inc. Subordinate Voting Shares
FA <GO> NYSE RQD COCKPIT → CIK 0001848731 ↗ Health Care • Medicinal Chemicals and Botanical Products
$2.28 ▲ +0.03
(+1.33%)
MKT CAP: $200.6M • VOL: 901.6K
52W L $2 52W H $14
GLAS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $182.0M | $200.9M | $160.8M |
| YoY Revenue Growth % | -9.4% | +24.9% | — |
| Gross Profit | $77.0M | $97.4M | — |
| Gross Margin % | 42.3% | 48.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.5M | $5.7M | -$49.5M |
| Operating Margin % | -9.1% | 2.9% | -30.8% |
| Net Income (GAAP) | -$29.7M | $519.0K | -$98.3M |
| EBITDA (Normalized) | $5.2M | $14.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $11.4M | $28.4M | $23.2M |
| Capital Expenditures (CapEx) | $27.2M | $10.3M | — |
| Free Cash Flow (FCF) | -$15.7M | $18.1M | $23.2M |
| FCF Margin % | -8.6% | 9.0% | 14.4% |
| Return on Invested Capital (ROIC %) | -9.2% | 2.7% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $68.6M | $50.6M | — |
| Total Stockholders' Equity | $73.9M | $116.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GLAS.